区域贫困指数可识别骨肉瘤生存差异而其他社会健康决定因素不能
单机构回顾性研究纳入88例2010至2024年诊断的高级别骨肉瘤儿童、青少年及年轻成人,比较区域贫困指数(ADI)与其他社会健康决定因素(SDOH)指标与就诊表现、治疗启动完成及生存的关系。高剥夺组更常急诊就诊、症状持续时间更长,5年总生存与局部无复发生存更差;ADI分组是独立死亡风险因素,而COI、贫困水平、保险类型或种族未显示生存差异。
要点
- 高ADI剥夺组更常急诊就诊(51% vs 22%),症状持续时间更长(13周 vs 6周)。
- 高ADI剥夺组5年总生存37% vs 65%,局部无复发生存81% vs 96%。
- 多变量Cox分析示ADI组(HR 2.0)和转移(HR 3.2)独立与死亡风险增加相关。
核心结论
- 高ADI剥夺组骨肉瘤患者总生存和局部无复发生存更差,ADI分组是独立死亡风险因素。
- 按COI、美国人口普查区贫困水平、保险类型或种族分层未见生存差异。
- 不同SDOH指标分层可给出矛盾结果,研究差异时应谨慎选择指标。
研究设计与样本
- 单机构回顾性比较研究,纳入88例2010至2024年诊断的高级别骨肉瘤儿童、青少年和年轻成人。
- ADI分为低剥夺(<75百分位)和高剥夺(≥75百分位)组,COI分为低机会(≤25百分位)和高机会(>25百分位)。
- 收集年龄、性别、原发部位、转移、化疗方案、手术、化疗反应及生存结局等资料。
主要发现
- 高剥夺组更常急诊就诊(51% [20/39] vs 22% [10/45],OR 1.9 [95%CI 1.2-2.9],p=0.006)。
- 高剥夺组症状持续时间更长(中位13周 [IQR 6-22] vs 6周 [IQR 4-11],p=0.002)。
- 高剥夺组5年总生存37% [95%CI 21%-53%] vs 65% [95%CI 49%-78%],p=0.04。
- 高剥夺组5年局部无复发生存81% [95%CI 63%-91%] vs 96% [95%CI 76%-99%],p=0.03。
- 多变量Cox分析示ADI组(HR 2.0 [95%CI 1.1-3.9])和转移(HR 3.2 [95%CI 1.7-6.4])独立与死亡风险增加相关。
关键数值与推荐
- ADI≥75百分位定义为高剥夺,<75百分位为低剥夺;COI≤25百分位为低机会,>25百分位为高机会。
- 医疗补助和无保险患者完成计划化疗的总治疗时间中位百分比大于商业保险患者(131% [IQR 122%-154%] vs 122% [IQR 113%-132%],p=0.01)。
临床怎么用
- 在骨肉瘤患儿中可使用ADI等侧重收入的SDOH指标识别生存差异高风险人群。
- 高ADI剥夺组患者更常急诊就诊且症状持续时间长,提示需关注就诊路径和早期识别。
局限性
- 单机构回顾性研究,样本量88例,结论外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Large database studies have demonstrated an association between measures of affluence and survival outcomes for patients with osteosarcoma. However, some recent reports have suggested that these disparities may not be as present in the pediatric population. It is unknown which measure of social determinants of health (SDOH) best captures outcome disparities, such as geospatial measures like the Area Deprivation Index (ADI) or patient-level measures such as insurance type or poverty rates, for osteosarcoma. QUESTIONS/PURPOSES: (1) Are different measures of SDOH associated with differences in the presentation of osteosarcoma, (2) differences in the initiation and completion of treatment, and (3) differences in survival outcomes? METHODS: This was a single-institution, retrospective, comparative study of 88 children, adolescents, and young adults diagnosed with high-grade osteosarcoma between 2010 and 2024. The ADI and other measures of SDOH previously investigated by other authors, including the Childhood Opportunity Index (COI), insurance type, US Census Tract poverty level, and self-reported race or ethnicity, were determined for each patient. The ADI scores were grouped into low (< 75th percentile) and high (≥ 75th percentile) deprivation groups, and the COI was classified as low (≤ 25th percentile) and high (> 25th percentile) opportunity, based on prior National Cancer Database (NCDB) and Surveillance, Epidemiology, and End Results (SEER) studies, which showed worse outcomes in patients in the bottom quartile of income. Data on patient age, gender, primary site, presence of metastasis, treatment including chemotherapeutic regimen and surgical treatment, chemotherapeutic response, and outcomes (including overall survival, metastasis-free survival, local recurrence-free survival, and relapse-free survival) were gathered from the medical record. Whether the patient presented to an acute care setting (urgent care or emergency department) or outpatient clinic was recorded. Patients with Medicaid and those with no insurance were compared with those with commercial insurance. Symptom duration before diagnosis and treatment timelines were compared against various measures of SDOH. Survival outcomes were also compared among SDOH groups. A multivariable Cox regression analysis including ADI group, tumor size, and presence of metastatic disease was performed to look for factors independently associated with survival. RESULTS: Patients in the high deprivation group presented to an acute care setting more frequently than the low deprivation group (51% [20 of 39] versus 22% [10 of 45], OR 1.9 [95% confidence interval (CI) 1.2 to 2.9]; p = 0.006) and had greater median (IQR) symptom duration (13 weeks [6 to 22] versus 6 weeks [4 to 11]; p = 0.002). The COI, US Census Tract poverty level, or race and ethnicity groups did not differ in symptom duration or presentation. The time to begin and complete treatment after diagnosis did not differ among the ADI, COI, US Census Tract poverty level, or race and ethnicity groups. The total median (IQR) treatment time was greater in those with Medicaid and patients without insurance compared with those with commercial insurance who completed planned chemotherapy (131% [122% to 154%] versus 122% [113% to 132%]; p = 0.01). Overall survival in the high deprivation group was worse compared with the low deprivation group (5-year overall survival 37% [95% CI 21% to 53%] versus 65% [95% CI 49% to 78%]; p = 0.04) as was local recurrence-free survival in the high deprivation group (5-year local recurrence-free survival 81% [95% CI 63% to 91%] versus 96% [95% CI 76% to 99%]; p = 0.03). A multivariable Cox regression survival analysis including ADI group, tumor size, and metastatic disease at presentation found that ADI group (HR 2.0 [95% CI 1.1 to 3.9]) and metastatic disease at presentation (HR 3.2 [95% CI 1.7 to 6.4]) were independently associated with an increased risk of death. There was no difference in survival when stratified by COI, US Census Tract poverty level, insurance type, or race and ethnicity. CONCLUSION: Stratifying pediatric and young adult patients with osteosarcoma by the ADI, which heavily favors income, identified patients with worse survival outcomes and agrees with large NCDB and SEER database studies showing survival disparities among income groups. Importantly, we show how stratifying patient groups by differing SDOH measures can give conflicting results and highlight the importance of careful SDOH measure selection. The ADI, or other measures that heavily weigh income, should be used when examining disparities that are found among income groups in the NCDB or SEER studies. Large database studies have demonstrated disparities in many orthopaedic diseases and procedures, and investigators who wish to study these further at an institutional level should choose a concordant measure of SDOH. LEVEL OF EVIDENCE: Level III, prognostic study.
引用
- Richardson SM, Johnson BA, Almalahi AM, et al. The Area Deprivation Index Identifies Survival Disparities in Osteosarcoma When Other Social Determinants of Health Do Not. Clin Orthop Relat Res. 2026. PMID: 42714329. doi:10.1097/CORR.0000000000004120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。